

## Naushin Hooda, R.Ph., Pharm.D., H.Bsc., B.Sc.

SENIOR EPIDEMIOLOGIST I

### CONTACT INFORMATION

---

EpidStrategies, a Division of ToxStrategies LLC  
10520 Yonge Street, Unit 35B  
Suite #208  
Richmond Hill, Ontario  
L4C 3C7  
Phone (240) 552-9474, x8017  
[nhooda@epidstrategies.com](mailto:nhooda@epidstrategies.com)

### PROFESSIONAL PROFILE

---

Dr. Naushin Hooda is a Doctor of Pharmacy, based in Toronto, Ontario. She has 5 years of professional experience, during and following her doctoral work, gaining broad expertise in the medical treatment and pharmaceutical arena within the Canadian clinical practice and pharmaceutical regulatory framework. Dr. Hooda's expertise is not limited to Canada, however. Most recently, she worked on medical strategic planning for a major pharmaceutical company's respiratory vaccine product in development for the U.S. market. During this process, she helped identify opportunities for scientific growth, conducted data needs assessment with engagement of key stakeholders, and executed initiatives such as real-world evidence generation, publication planning, and development of continuing education for medical providers.

Dr. Hooda's experience includes work in health and pharmacy business development, direct patient care services in multiple health-care facilities, and a position as a post-doctoral medical affairs resident for the Canadian arm of a pharmaceutical developer/manufacturer. During her doctoral work, she gained experience collaborating with organizations outside of academia, and she was awarded multiple scholarships and awards for academic excellence, research, leadership, community initiatives, and overall contributions to pharmacy.

## EDUCATION AND DEGREES EARNED

---

- 2019 Doctor of Pharmacy, (Dean's List)  
University of Waterloo, School of Pharmacy, Waterloo, Ontario
- 2019 Bachelor of Science in Biomedical Sciences  
University of Waterloo, Faculty of Science, Waterloo, Ontario
- 2016 Bachelor of Science in Human Biology (Specialist) and Psychology (Minor), with Distinction  
University of Toronto, Faculty of Arts and Science, Toronto, Ontario

## PROFESSIONAL AFFILIATIONS

---

- Ontario College of Pharmacists (OCP) — Registered Pharmacist
- Ontario Pharmacists' Association (OPA) — Member & Selected Feature (*International Women's Day & Pharmacist Awareness Month*)
- Canadian Association of Pharmacy in Oncology (CAPHO) — Awards Committee Member, Chapter Founder & Past Chapter President
- Science-to-Business Network (S2BN) — Chapter Founder & Past Chapter Director
- Canadian Society of Hospital Pharmacists (CSHP) — Member
- Canadian Agency for Drugs and Technologies Assessment (CADTH) — 2020 Conference Working Group
- Medical Affairs Professional Society — Member
- Women in the Enterprise of Science & Technology — Member

## RECOGNITIONS/AWARDS

---

- 2019 President Recognition Award, University of Waterloo
- 2019 Leadership Award, Society of Pharmacy Students
- 2019 Student of Distinction Award, Ontario Pharmacists Association
- 2019 GSK/CSPS National Undergraduate Student Research Program Award, Canadian Society of Pharmaceutical Sciences
- 2018 Atkinson Citizenship Award, University of Waterloo Faculty of Science
- 2018 Centennial Leadership Award, Canadian Pharmacists' Association
- 2018 Guy Genest Passion for Pharmacy Award, Canadian Association for Pharmacy Students and Interns
- 2017 Student Member Award, Canadian Association of Pharmacy in Oncology
- 2015 Letter Award, University of Toronto

## SELECTED PROFESSIONAL EXPERIENCE

---

### *Pharmaceutical Industry*

Contributed to medical strategic planning for a respiratory vaccine pipeline product in the US market through the identification of key opportunities for scientific growth, data needs assessment with internal and external stakeholder engagement, and execution of joint initiatives, including externally sponsored research, real-world evidence generation, publication planning, and development of continuing medical education for health-care professionals.

Collaborated cross-functionally to objectively communicate balanced scientific and medical information on emerging data, including the development of presentations and information materials

Led the digital transformation of the external stakeholder engagement medium to incorporate platforms such as Within3, to facilitate operations during COVID-19.

Developed research protocols and manuscripts for publication through partnership with external collaborators and internal groups, including pharmacovigilance, health economics and outcomes research, vaccine epidemiology, and mathematical modeling, leading to the development and execution of protocols for three studies, including implementation of the company's first paperless survey utilizing electronic data capture tools.

Received corporate recognition for contributions to the global branding and contributions to the company's leadership program, a 3-year program for dual doctorate/MBA students.

Led the development of a vaccine-related business case study that was submitted to the Wharton Business School and selected for use in a first-year MBA course.

### *Clinical Pharmacy*

Developed expertise in oncology, emergency, long-term care, and critical care settings

Conceptualized and launched a novel emergency room triage workflow in a rural hospital that incorporated a student pharmacist into the roles of medication assessment on triage, preliminary patient physical assessment, and post-diagnosis therapy selection, resulting in shorter wait times and enhanced satisfaction expressed by both patients and physicians.

Proposed innovative strategies, order sets, and protocols to meet hospital accreditation standards in accordance with relevant governing bodies, while minimizing drug waste and costs, and upholding patient safety standards.

Served as liaison with Cancer Care Ontario to implement a community-wide colorectal cancer screening plan for a rural community, including the design of a media/outreach campaign and patient communication tool, to ease the provincial transition to the fecal immunochemical test (FIT), addressing the unique systematic challenges and barriers of rural communities.

Contributed pharmaceutical expertise to the development of a computerized algorithm designed to screen, identify, and manage high-risk patients being treated with opioids, using electronic medical record software.

Led the national launch of a branded harm reduction and opioid crisis management support center for a large Canadian pharmacy retail chain for >1000 stores, including the development of opioid replacement therapy programs for pharmacy use in six provinces.

## MANUSCRIPTS

---

Yoshino T, **Hooda N**, Younan D, Muro K, Shitara K, Heinemann V, ... Suh M, Reichert H, Mezzi K, Fryzek J, et al. 2024. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. *Eur J Cancer* 202:113975, doi: 10.1016/j.ejca.2024.113975.

Mitchell M, Suh M, **Hooda N**, Bylsma LC, Cohen S. 2024. The effect of bovine dairy products and their components on the incidence and natural history of infection: A systematic literature review. *Nutr J* 23:26; [online open access](#).

Suh M, Mitchell M, **Hooda N**, Bylsma LC, Cohen SS. 2024. The effects of dairy consumption on vaccine immune response and immunoglobulins: A systematic literature review. *Int J Nutr* 8(1):1–25; DOI [10.14302/issn.2379-7835.ijn-24-4938](https://doi.org/10.14302/issn.2379-7835.ijn-24-4938).

Movva N, Reichert H, **Hooda N**, Bylsma LC, Mitchell M, Cohen SS. 2023. Dietary eating patterns, dairy consumption, and anxiety: A systematic literature review. *PLoS One* 18(12):e0295975. doi: 10.1371/journal.pone.0295975. PMID: 38153944.

Bylsma LC, Pundole X, Ju C-H, **Hooda N**, Movva N, Elkhoully E, Bebb G, Fryzek J, et al. 2023. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. *Target Oncol* [[open access](#)].

Broome CM, **Hooda N**, Su J, Jiang X, Nicholson G, Frankenfeld CL, Iglesias-Rodriguez M, Fryzek J, Patel Parija. 2022. Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States. *PLOS ONE* open access, <https://doi.org/10.1371/journal.pone.0276617>.

Anneberg M, Svane HML, Fryzek J, Nicholson G, White JB, Edris B, Smith LM, **Hooda N**, Petersen MM, Baad-Hansen T, Keller JØ, Jørgensen PH, Pedersen AB. 2022. The epidemiology of desmoid tumors in Denmark. *Cancer Epidemiol* 77:102114, <https://doi.org/10.1016/j.canep.2022.102114>.

Elbeddini A, Tayefehchamani Y, Davey M, Gallinger J, **Hooda N**, Aly A, Erickson D, Lee S. 2021. Fournier's gangrene with dapagliflozin in a rural hospital: A case report. *BMJ Case Rep* 14(2):e237784, doi: 10.1136/bcr-2020-237784.

Vágó EK, Nicholson G, Horváth-Puhó E. **Hooda N**, Fryzek JP, Su J. 2021. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. *Curr Med Res Opin*, open access, <https://doi.org/10.1080/03007995.2021.1960494>.

Elbeddini A, **Hooda N**, Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. *Am J Case Rep*, doi: 10.12659/AJCR.924058.

Elbeddini A, **Hooda N**, Yang L. 2020. Role of Canadian pharmacists in managing drug shortage concerns amid the COVID-19 pandemic. *Canadian Pharmacists J*, doi: 10.1177/1715163520929387.

**Hooda N**, Quinn E, DeAngelis C, Pasetka M, McFarlane T. 2019. Delayed CINV in FOLFOX chemotherapy: A retrospective chart review comparing two Ontario hospitals. *J Oncol Pharmacy Prac* (abstract 22), doi: 10.1177/1078155219834495.

## ABSTRACTS AND PRESENTATIONS

---

Yoshino T, **Hooda N**, Younan D, Shitara K, Heinemann V, ... Suh M, Reichert H, ... Fryzek J, et al. 2023. 127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness. *Ann Oncol* 34(Suppl 4):S1519 [abstract]; DOI:<https://doi.org/10.1016/j.annonc.2023.10.262>.

Pundole X, Ju C-H, Bylsma LC, **Hooda N**, Movva N, Elkhoully E, Bebb DG, Fryzek J, et al. 2023. Prevalence of delta-like ligand 3 expression in small cell lung cancer. *J Clinical Oncology* 41:16\_suppl e20618

**Hooda N**, Svane HML, Fryzek J, Nicholson G, White JB, Edris B, Smith LM, Petersen MM, Baad-Hansen T, Keller JØ, Jørgensen PH, Pedersen AB. 2021. The epidemiology of desmoid tumors in Denmark. Poster presented at the Connective Tissue Oncology Society Annual Meeting, November 2021.

Vágó EK, Nicholson G, Horváth-Puhó E, **Hooda N**, Fryzek J, Su J. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. E-poster presentation to European Hematology Association Virtual Congress, June 2021.

Fergie J, Gonzales T, Suh M, Jiang X, Fryzek JP, **Hooda N**, Howard A, Bloomfield A. Higher-risk congenital heart disease (CHD) among children aged  $\leq 24$  months with respiratory syncytial virus hospitalizations (RSVH) and all-cause bronchiolitis hospitalizations (BH). 37th Annual Children's National Symposium: ECMO and the Advanced Therapies for Cardiovascular and Respiratory Failure, Feb 2021.

Fergie J, Gonzales T, Suh M, Jiang X, Fryzek J, **Hooda N**, Howard A, Bloomfield A. Higher-risk congenital heart disease (CHD) among children aged  $\leq 24$  months with respiratory syncytial virus hospitalizations (RSVH) and all-cause bronchiolitis hospitalizations (BH) at RSV season before and after the 2014 American Academy of Pediatrics (AAP) guidance. California Association of Neonatologists' 27th Annual Cool Topics in Neonatology Conference, March 2021.

**Hooda N**, McFarlane T, Pasetka M, DeAngelis C. Chemotherapy-induced nausea and vomiting (CINV) in colorectal cancer (CRC) patients undergoing FOLFOX Chemotherapy: A retrospective chart review comparing two Ontario hospitals. Abstract accepted for publication in *J Pharmacy Pharmaceut Sci*. Poster presented at the Canadian Society for Pharmaceutical Sciences Annual Conference, Vancouver, BC, May 2019.

**Hooda N**, Quinn E, DeAngelis C, Pasetka M, McFarlane T. 2019. Delayed CINV in FOLFOX chemotherapy: A retrospective chart review comparing two Ontario hospitals. Poster presented at the Canadian Association for Pharmacy in Oncology Annual Conference, Halifax, NS, April 2019.

**Hooda N**, McFarlane T, Pasetka M, DeAngelis C. 2018. Investigating guideline-consistent anti-emetic prescribing practices at the Odette Cancer Centre (OCC). Poster for oral presentation seminar, "Meet the Future Leaders in Research," at the Ontario Pharmacist Conference, Huntsville, ON, June 2018.

## CERTIFICATIONS AND TRAINING

---

2020–2021	Drug Safety and Effectiveness Cross-Disciplinary Training Program, Canadian Institute of Health Research
2019–2020	Industrial Pharmacy Residency Program (IPRP), Faculty of Pharmacy, University of Toronto
2019	Canadian Pharma Market Regulations, Pharmaceutical Advertising Advisory Board
2018	Health Coaching Cardiovascular Program, Green Shield Canada
2015	Researchers Conducting Retrospective Review of Health Records, Hamilton Health Sciences

## PROTOCOL REGISTRATIONS

---

Bylsma L, Fryzek J, Movva N, Frankenfeld C, **Hooda N**, Pundole X, et al. 2022. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. PROSPERO 2022 CRD42022351119

Mitchell M, Cohen S, Movva N, Bylsma L, **Hooda N**. 2022. Systematic review of the potential association dietary eating patterns (specifically \*including\* whole dairy products) and anxiety in humans. PROSPERO 2022 CRD42022333785